Statins and safety: Applying the results of randomized trials to clinical practice

American Journal of Cardiology

Volumn 92, Issue 6, 2003, Pages 692-695

  Waters, David ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

CANCER; CARDIOVASCULAR RISK; CATARACT; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEPRESSION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HEART INFARCTION; HEMORRHAGIC SHOCK; HUMAN; HYPERCHOLESTEROLEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; MEDICAL LITERATURE; MENTAL DEFICIENCY; MORTALITY; MYOPATHY; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; SURGICAL TECHNIQUE;

EID: 0041333803     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00825-7     Document Type: Note

References (37)

1. Newman C.B., Palmer G., Silbershatz H., Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 92:2003;670-676.
2. Ravnskov U. Cholesterol lowering trials in coronary heart disease frequency of citation and outcome. BMJ. 305:1992;15-19.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.C., David B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
6. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
7. Downs J.R., Clearfield M., Weiss S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomized placebo-controlled trial. Lancet. 360:2002;7-22.
9. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients with average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicenter randomized controlled trial. Lancet. 361:2003;1149-1158.
10. Waters D., Lespérance J., Gladstone P., Boccuzzi S.J., Cook T., Hudgin R., Krip G., Higginson L. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation. 94:1996;614-621.
11. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomized controlled trial. Lancet. 360:2002;1623-1630.
12. Law M.R., Wald N.J. Risk factor thresholds their existence under scrutiny. BMJ. 324:2002;1570-1576.
13. Jacobs D., Blackburn H., Higgins M., Reed D., Iso H., McMillan G., Neaton J., Nelson J., Potter J., Rifkind B., et al. Report of the Conference on Low Blood Cholesterol mortality associations. Circulation. 86:1992;1046-1060.
14. Eckernas S.A., Roos B.E., Kvidal P., Eriksson L.O., Block G.A., Neafus R.P., Haigh J.R. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep a comparison of two structurally different HMG CoA reductase inhibitors in patients with moderate hypercholesterolemia. Br J Clin Pharmacol. 35:1993;284-289.
15. Keech A.C., Armitage J.M., Wallendszus K.R., Lawson A., Hauer A.J., Parish S.E., Collins R. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group. Br J Clin Pharmacol. 42:1996;483-490.
16. Harrison R.W., Ashton C.H. Do cholesterol lowering agents affect brain activity? A comparison of simvastatin, pravastatin and placebo in healthy volunteers. Br J Clin Pharmacol. 37:1994;231-236.
17. Gengo F., Cwudzinski D., Kinkel P., Block G., Stauffer L., Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 18:1995;209-214.
18. Laties A.M., Shear C.L., Lippa E.A., Gould A.L., Taylor H.R., Hurley D.P., Stephenson W.P., Keates E.U., Tupy-Visich M.A., Chremos A.N. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of human lens after 48 weeks of treatment with lovastatin. Am J Cardiol. 67:1991;447-453.
19. Schlienger R.G., Haefeli W.E., Jick H., Meier C.R. Risk of cataract in patients treated with statins. Arch Int Med. 161:2001;2021-2026.
20. Tolman K.G. The liver and lovastatin. Am J Cardiol. 89:2002;1374-1380.
21. Downs J.R., Clearfield M., Tyroler H.A., Whitney E.J., Kruyer W., Langendorfer A., Zagrebelsky V., Weis S., Shapiro D.R., Beere P.A., Gotto A.M. Jr. Additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 87:2001;1074-1079.
22. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 346:2002;539-540.
23. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA. 289:2003;1681-1690.
24. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Downton M., Franklin F.A., Gould L., Hesney M., Higgins J., Hurley D.P., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Int Med. 151:1991;43-49.
25. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., England J.D.F. Statin-associated myopathy with normal creatine kinase levels. Ann Int Med. 137:2002;581-585.
26. Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA. 275:1996;55-60.
27. Bjerre L.M., LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 110:2001;716-723.
28. Coogan P.F., Rosenberg L., Palmer J.R., Strom B.L., Zauber A.G., Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiol. 13:2002;262-267.
29. Kaye J.A., Meier C.R., Walker A.M., Jick H. Statin use, hyperlipidemia, and the risk of breast cancer. Br J Cancer. 86:2002;1436-1439.
30. Beck P., Wysowski D.K., Downey W., Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol. 56:2003;280-285.
31. Wong W.W., Dimitroulakos J., Minden M.D., Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 16:2002;508-519.
32. Seeger H., Wallwiener D., Mueck A.O. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes. 111:2003;47-48.
33. Collisson E.A., Carranza D.C., Chen I.Y., Kolodney M.S. Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J Invest Dermatol. 119:2002;1172-1176.
34. Jackevicius C.A., Mamdami M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 288:2002;462-467.
35. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 288:2002;455-461.
36. Athyros V.G., Papageorgiou A.A., Mercouris B.R., Athyrou V.V., Symeonidis A.N., Basayannis E.O., Demitriadis D.S., Kontopoulos A.G. Treatment with atorvastatin to the National Cholesterol Education Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 18:2002;220-228.
37. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study a randomized controlled trial. JAMA. 285:2001;1711-1718.